Published in Proc Natl Acad Sci U S A on March 30, 2015
MEK inhibition abrogates sunitinib resistance in a renal cell carcinoma patient-derived xenograft model. Br J Cancer (2016) 1.39
Loss of CD73-mediated actin polymerization promotes endometrial tumor progression. J Clin Invest (2015) 0.94
Malignant inflammation in cutaneous T-cell lymphoma-a hostile takeover. Semin Immunopathol (2016) 0.87
CD14/TLR4 priming potentially recalibrates and exerts anti-tumor efficacy in tumor associated macrophages in a mouse model of pancreatic carcinoma. Sci Rep (2016) 0.76
AMPKα Is Suppressed in Bladder Cancer through Macrophage-Mediated Mechanisms. Transl Oncol (2016) 0.75
The role of PIM1/PIM2 kinases in tumors of the male reproductive system. Sci Rep (2016) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
The hallmarks of cancer. Cell (2000) 113.05
Inflammation and cancer. Nature (2002) 53.78
Cancer-related inflammation. Nature (2008) 34.21
Immunity, inflammation, and cancer. Cell (2010) 28.27
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell (1996) 23.99
Fibroblasts in cancer. Nat Rev Cancer (2006) 18.95
Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol (2002) 17.85
Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med (1986) 17.64
Macrophage diversity enhances tumor progression and metastasis. Cell (2010) 13.41
Matrix metalloproteinases: regulators of the tumor microenvironment. Cell (2010) 12.90
Alternative activation of macrophages: mechanism and functions. Immunity (2010) 12.43
Paradoxical roles of the immune system during cancer development. Nat Rev Cancer (2006) 10.57
Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol (2010) 9.59
The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer (2008) 7.40
gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell (2009) 6.26
The biology of cancer stem cells. Annu Rev Cell Dev Biol (2007) 6.23
Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer (2006) 5.60
Tumors as organs: complex tissues that interface with the entire organism. Dev Cell (2010) 3.98
Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc Natl Acad Sci U S A (2009) 3.87
The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med (2008) 3.68
CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell (2011) 3.41
Hedgehog/Wnt feedback supports regenerative proliferation of epithelial stem cells in bladder. Nature (2011) 3.15
Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol (2013) 2.92
Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res (2005) 2.91
STAT3-driven upregulation of TLR2 promotes gastric tumorigenesis independent of tumor inflammation. Cancer Cell (2012) 2.66
Cancer-related inflammation: common themes and therapeutic opportunities. Semin Cancer Biol (2011) 2.45
Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity. Cancer Metastasis Rev (2010) 2.41
Recent advances in cancer stem cells. Curr Opin Genet Dev (2008) 2.17
Tumor-associated neutrophils: friend or foe? Carcinogenesis (2012) 2.15
The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology (2013) 2.14
Polarized immune responses differentially regulate cancer development. Immunol Rev (2008) 1.95
Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment. Clin Exp Immunol (2012) 1.90
Tie2-expressing monocytes: regulation of tumor angiogenesis and therapeutic implications. Trends Immunol (2007) 1.84
TLR accessory molecules. Curr Opin Immunol (2008) 1.84
CD14 is a coreceptor of Toll-like receptors 7 and 9. J Exp Med (2010) 1.64
Three differentiation states risk-stratify bladder cancer into distinct subtypes. Proc Natl Acad Sci U S A (2012) 1.60
Tumor metabolism of lactate: the influence and therapeutic potential for MCT and CD147 regulation. Future Oncol (2010) 1.54
Chronic inflammation and bladder cancer. Urol Oncol (2007) 1.45
Corrupt policemen: inflammatory cells promote tumor angiogenesis. Curr Opin Oncol (2009) 1.29
Circulating and tumor-infiltrating myeloid cell subsets in patients with bladder cancer. Int J Cancer (2011) 1.27
Serum biomarkers for improved diagnostic of pancreatic cancer: a current overview. J Cancer Res Clin Oncol (2010) 1.20
Unraveling the obesity and breast cancer links: a role for cancer-associated adipocytes? Endocr Dev (2010) 1.18
Bioimmunotherapy for melanoma using fully human antibodies targeting MCAM/MUC18 and IL-8. Pigment Cell Res (2006) 1.17
Interleukin-8 secretion by ovarian cancer cells increases anchorage-independent growth, proliferation, angiogenic potential, adhesion and invasion. Cytokine (2012) 1.13
Interleukin-6 signaling regulates anchorage-independent growth, proliferation, adhesion and invasion in human ovarian cancer cells. Cytokine (2012) 1.11
Blocking TLR2 activity attenuates pulmonary metastases of tumor. PLoS One (2009) 1.10
Tumor microenvironment and myeloid-derived suppressor cells. Cancer Microenviron (2012) 1.03
Adenovirus CD40 ligand gene therapy counteracts immune escape mechanisms in the tumor Microenvironment. J Immunol (2004) 0.97
MB49 murine urothelial carcinoma: molecular and phenotypic comparison to human cell lines as a model of the direct tumor response to bacillus Calmette-Guerin. J Urol (2009) 0.92
Interleukin-12 immunotherapy of murine transitional cell carcinoma of the bladder: dose dependent tumor eradication and generation of protective immunity. J Urol (2004) 0.85
In vitro cultivation of epithelial cells derived from tumors of the human urinary tract. Cancer Res (1976) 0.81
Biomolecular cytokine therapy. Pathol Oncol Res (2003) 0.81